Adicet Bio, Inc. (ACET)
NCM · Healthcare · Biotechnology
$9.52
-0.10%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$89.1M
Shares Outstanding
9.4M
Exchange
NCM
Currency
USD
About Adicet Bio, Inc.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (28.0M) | (31.9M) | (21.6M) | (22.3M) |
| Net Income | (26.9M) | (30.5M) | (20.2M) | (21.4M) |
| Diluted EPS | $-4.64 | $-2.94 | $-1.88 | $-1.99 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 25.0M | 0.00 | 0.00 | 0.00 |
| Operating Income | (72.6M) | (132.6M) | (127.6M) | (122.1M) |
| Net Income | (69.8M) | (142.7M) | (117.1M) | (116.8M) |
| Diluted EPS | $-27.20 | $-52.96 | $-21.28 | $-16.95 |